Platinum-based therapy selects for an angiogenic enriched tumor micro-environment in High Grade Serous Ovarian Cancer


  1. Angiogenesis is a key pathological feature of epithelial ovarian cancer (EOC) and anti-angiogenics have dominated the field of drug development in EOC
  2. There are no clinically approved predictive biomarker to preselect the subgroup of high grade serous ovarian cancer (HGSOC) that will derive benefit from anti-angiogenic therapy
  3. Relapse post platinum-based therapy is associated with a beneficial response to anti-angiogenics
  4. Innate and acquired platinum resistance is characterized by upregulation of VEGFa and receptor tyrosine kinase expression that trigger an enriched angiogenic tumor micro-environment
  5. In-vitro and in-vivo angiogenesis assays demonstrate that platinum resistant cell lines are sensitive to Cediranib and Nintedanib

Click here to read more